Whitehouse Scientific’s managing director, Jamie Storey, showed his support for ‘Movember’ by joining more than 850,000 fellow ‘Mo Bros’ from around the world in growing facial hair throughout the month of November.
From humble beginnings, ‘Movember’ has become a global campaign aimed at raising vital funds and awareness for men’s health, specifically prostate and testicular cancer. It is one of a number of charity initiatives supported by the Whitehouse Scientific team.
‘Although I have spent the month looking a bit of a fool it was worth it for such a great cause,’ said Storey.
‘With awareness being the key, it was a pleasure explaining why I had grown a handlebar moustache to the many who have asked. I look forward to trying out a new style next year.’
Funds raised by ‘Movember’ in the UK are directed to The Prostate Cancer Charity and Institute of Cancer Research, which supports programmes aimed at increasing early cancer detection, diagnosis and effective treatments, and ultimately reducing the number of preventable deaths.
To date, ‘Movember’ has raised nearly £65m, with £15m coming from the UK. A total of £170m has been collected since 2004.
Whitehouse md grows moustache for charity
Joins fellow ‘Mo Bros’ around the world to raise funds and awareness for men’s health
You may also like
Manufacturing
ITT to acquire SPX FLOW in $4.8bn deal, expanding global leadership in engineered components and flow technologies
Acquisition strengthens ITT’s position in industrial, chemical, energy, health and nutrition markets, adding high-margin revenue, major aftermarket growth and $80m in expected synergies by year three
Finance
EIB and Angelini Ventures launch €150m fund to boost European biotech, medtech and digital health startups
The EIB and Angelini Ventures will co-invest €150 million to scale innovative European healthtech companies. The deal marks the EIB’s first partnership with a corporate venture capital fund in the healthcare sector
Finance
Fresh capital flows into neurodegeneration, cancer and vascular-access developers
A string of funding rounds and strategic financing deals across Europe’s life-sciences sector is breathing new life into companies working on high-need treatments — from neurodegeneration to cancer and dialysis access